Ola Junghard

Summary

Affiliation: AstraZeneca R and D

Publications

  1. pmc The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials
    Michael Shaw
    Park Nicollet Clinic and University of Minnesota Medical School, Minneapolis, MN 55416 2699, USA
    Health Qual Life Outcomes 6:31. 2008
  2. ncbi Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials
    O Junghard
    Dept of Clinical Science, AstraZeneca R and D Molndal, Sweden
    Scand J Gastroenterol 38:1197-9. 2003
  3. ncbi The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH
    Ola Junghard
    AstraZeneca R and D Molndal, 431 83 Mölndal, Sweden
    Eur J Clin Pharmacol 58:453-8. 2002
  4. doi Validation of a four-graded scale for severity of heartburn in patients with symptoms of gastroesophageal reflux disease
    Ola Junghard
    Biostatistics, AstraZeneca R and D, Molndal, Sweden
    Value Health 11:765-70. 2008
  5. pmc Responsiveness of measures of heartburn improvement in non-erosive reflux disease
    Ola Junghard
    Biostatistics, AstraZeneca R and D, Molndal, Sweden
    Health Qual Life Outcomes 5:32. 2007
  6. ncbi Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease
    Ola Junghard
    Biostatistics, AstraZeneca R and D, Molndal, Sweden
    Eur J Gastroenterol Hepatol 19:555-60. 2007
  7. ncbi Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Sweden
    Pharmacoeconomics 20:279-87. 2002
  8. ncbi Factor structure of the Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire evaluated in patients with heartburn predominant reflux disease
    Károly R Kulich
    AstraZeneca R and D Molndal, Molndal, Sweden
    Qual Life Res 12:699-708. 2003
  9. doi Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda study
    E Bolling-Sternevald
    Centre for Family and Community Medicine, Karolinska Institutet, Stockholm, Sweden
    Dig Dis 26:256-63. 2008
  10. ncbi Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?
    E Bolling-Sternevald
    Department of Biomedicine and Surgery, Linkoping, Sweden
    Aliment Pharmacol Ther 18:117-24. 2003

Detail Information

Publications16

  1. pmc The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials
    Michael Shaw
    Park Nicollet Clinic and University of Minnesota Medical School, Minneapolis, MN 55416 2699, USA
    Health Qual Life Outcomes 6:31. 2008
    ....
  2. ncbi Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials
    O Junghard
    Dept of Clinical Science, AstraZeneca R and D Molndal, Sweden
    Scand J Gastroenterol 38:1197-9. 2003
  3. ncbi The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH
    Ola Junghard
    AstraZeneca R and D Molndal, 431 83 Mölndal, Sweden
    Eur J Clin Pharmacol 58:453-8. 2002
    ....
  4. doi Validation of a four-graded scale for severity of heartburn in patients with symptoms of gastroesophageal reflux disease
    Ola Junghard
    Biostatistics, AstraZeneca R and D, Molndal, Sweden
    Value Health 11:765-70. 2008
    ....
  5. pmc Responsiveness of measures of heartburn improvement in non-erosive reflux disease
    Ola Junghard
    Biostatistics, AstraZeneca R and D, Molndal, Sweden
    Health Qual Life Outcomes 5:32. 2007
    ..The aim of the study was to investigate the responsiveness of various treatment success variables in patients with symptoms of heartburn...
  6. ncbi Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease
    Ola Junghard
    Biostatistics, AstraZeneca R and D, Molndal, Sweden
    Eur J Gastroenterol Hepatol 19:555-60. 2007
    ....
  7. ncbi Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Sweden
    Pharmacoeconomics 20:279-87. 2002
    ..Clinical studies have demonstrated that esomeprazole is superior to omeprazole for the acute treatment of reflux oesophagitis...
  8. ncbi Factor structure of the Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire evaluated in patients with heartburn predominant reflux disease
    Károly R Kulich
    AstraZeneca R and D Molndal, Molndal, Sweden
    Qual Life Res 12:699-708. 2003
    ..To test whether the original factor structure of the Quality of Life in Reflux and Dyspepsia (QOLRAD) can be replicated in Nordic patients and English speaking patients...
  9. doi Do gastrointestinal symptoms fluctuate in the short-term perspective? The Kalixanda study
    E Bolling-Sternevald
    Centre for Family and Community Medicine, Karolinska Institutet, Stockholm, Sweden
    Dig Dis 26:256-63. 2008
    ..We aimed to determine gastrointestinal symptom fluctuation in an random adult population using a validated questionnaire assessing gastrointestinal symptoms...
  10. ncbi Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?
    E Bolling-Sternevald
    Department of Biomedicine and Surgery, Linkoping, Sweden
    Aliment Pharmacol Ther 18:117-24. 2003
    ..The efficacy of proton pump inhibitors in functional dyspepsia is modest and the prognostic factors are almost unknown...
  11. ncbi Self-administered symptom questionnaires in patients with dyspepsia and their yield in discriminating between endoscopic diagnoses
    E Bolling-Sternevald
    Department of Biomedicine, Linköping Hospital, Linkoping, Sweden
    Dig Dis 20:191-8. 2002
    ..We aimed at evaluating whether specific gastrointestinal symptoms, identified by self-administered questionnaires, correlate with specific endoscopic diagnoses and discriminate organic from functional dyspepsia...
  12. ncbi Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial
    E Bolling-Sternevald
    Dept of Biomedicine, Linkoping, Sweden
    Scand J Gastroenterol 37:1395-402. 2002
    ..The role of drug treatment remains controversial. The aim in this study was to evaluate the effect of omeprazole 20 mg twice daily (b.i.d) and to test methods for symptom assessment...
  13. ncbi Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies
    Peter Wahlqvist
    AstraZeneca R and D Molndal, Sweden
    Pharmacoeconomics 20:267-77. 2002
    ....
  14. ncbi Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients?
    Elaine McColl
    Centre for Health Services Research, School of Population and Health Sciences, University of Newcastle upon Tyne, 21 Claremont Place, Newcastle upon Tyne NE2 4AA, United Kingdom
    Am J Gastroenterol 100:11-8. 2005
    ..This study aimed to determine the extent of agreement between clinicians and patients regarding assessments of reflux symptom severity in patients with gastroesophageal reflux disease...
  15. ncbi Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers
    Clive H Wilder-Smith
    Gastrointestinal Unit and Gastrointestinal Physiology Laboratory, Bern, Switzerland
    Digestion 68:184-8. 2003
    ..To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers...
  16. doi Standardization of surgical technique in antireflux surgery: the LOTUS Trial experience
    Stephen E A Attwood
    Department of Surgery, Northumbria Healthcare, North Tyneside Hospital, Rake Lane, North Shields, NE29 8NH, United Kingdom
    World J Surg 32:995-8. 2008
    ..This study was designed to identify a methodology for standardization of surgical technique and to measure the effectiveness of this standardization...